Organization
The Cleveland Clinic Foundation
4 abstracts
Abstract
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).Org: The University of Sydney, University of Pittsburgh Medical Center, Medical University of Vienna, Perlmutter Cancer Center at NYU Langone Health Medical Center, Elbe Klinikum Buxtehude,
Abstract
Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001TGF-ß Trap.Org: University of Texas MD Anderson Cancer Center, The Cleveland Clinic Foundation, City of Hope National Medical Center, EpicentRx, Mary Crowley Cancer Research Center,
Abstract
Development of a postoperative nomogram to predict disease-specific mortality in gastric cancer: A competing risk analysis using variables the AJCC recommends be collected and registered.Org: Shizuoka Cancer Center, Nagaizumi, Japan, Division of Gastric Surgery, Department of Quantitative Health Sciences, The Cleveland Clinic Foundation, Cleveland Clinic Brunswick Urgent Care,
Abstract
Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.Org: Desert Surgical Oncology, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Castle Biosciences, Castle Biosciences, Inc.,